Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Of the big oncology deals since 2016, there are still plenty that could go either way.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.